In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Cibinetide (ARA-290) | Synthetic fragment BPC-157 | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic fragment | |
| Area | Recovery and repair | Recovery and repair | |
| Evidence | |||
| Amount of evidence | 366 | 987 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 10 (4 in people) | 24 (8 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 4 | 3 · 2 active1 more mentions it but does not test it | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Cibinetide (ARA-290) | BPC-157 |
|---|---|---|
| Wound healingSkin and wound | 271710 | 1301228 |
| Neuroprotection |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 30 Oct 2026).
397248 |
7474 |
| Inflammation markersSkin and wound | 926824 | 4141 |
|---|
| Receptor activity and mechanismWhole body | 211110 | 805129 |
|---|
| Adverse eventsWhole body | 936 | 24816 |
|---|
| Heart functionCardiovascular | 44 | 5656 |
|---|
| PainNervous system and cognition | 20614 | 15114 |
|---|
| Anxiety and moodMental health and mood | 651 | 2626 |
|---|
| Kidney functionKidney and urinary | 29218 | 1010 |
|---|
| Muscle injury and repairMusculoskeletal | 44 | 3434 |
|---|
| Immune responseKidney and urinary | 261169 | 66 |
|---|
| Liver fat and liver functionLiver | 11 | 28271 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Cibinetide (ARA-290) differs from Erythropoietin (human) at 7 positions.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Cibinetide (ARA-290) | BPC-157 |
|---|---|---|
| PainNervous system and cognitionCompared as: value in the arm that got the peptide, in points | −11.5 points SFNSL score change · ARA 290 Placebo: −2.9 points Dose studied: 2 mg three times weekly4 weeksn = 222012 | No randomized trial result 15 results from other study designs. |
| Exercise and physical functionNervous system and cognitionCompared as: value in the arm that got the peptide, in points | −14.6 points SF-36 physical functioning change · ARA 290 Dose studied: 2 mg three times weekly4 weeksn = 122012 | No randomized trial result 10 results from other study designs. |
−11.5 points
SFNSL score change · ARA 290
Placebo: −2.9 points
Dose studied: 2 mg three times weekly4 weeksn = 222012
No randomized trial result
15 results from other study designs.
−14.6 points
SF-36 physical functioning change · ARA 290
Dose studied: 2 mg three times weekly4 weeksn = 122012
No randomized trial result
10 results from other study designs.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 4 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
Araim Pharmaceuticals, Inc.64 participantsJan 2014 to Feb 2015
Neuropathy of Sarcoidosis
Leiden University Medical Center36 participantsFeb 2012 to Feb 2014
Depression
Claes-Göran Östenson24 participantsOct 2013 to est. Dec 2015
Diabetes Type 2 · Impaired Glucose Tolerance · Impaired Fasting Glucose
3 trials · 1 ongoing · 1 not yet recruiting · source ClinicalTrials.gov (opens in a new tab)
Hudson Biotech120 participants2 Feb 2026 to est. 17 Feb 2028
Hamstring Muscle Strain · Skeletal Muscle Injury
PharmaCotherapia d.o.o.42 participantsOct 2015 to est. Mar 2016
Healthy Volunteers
University of Arkansas30 participantsest. 1 Jan 2027 to est. 1 Aug 2027
Rotator Cuff Tear
1 more mentions it but does not test it. They only measure it or name it in their text.